MPS Pharmaa reports net loss of ₹1.02 cr as operations remain stalled
The company generated only ₹3.56 lacs in income for FY26, while auditors flagged unverified investments and stalled capital projects.
— 1 earlier story on MPS Pharmaa Ltd. →What's new
- FY26 income fell to ₹3.56 lacs from ₹4.77 lacs in the prior year.
- Auditors issued a qualified opinion on ₹53.80 lacs in investments and ₹2.41 cr in stalled capital work.
- Accumulated losses of ₹19.04 cr have nearly wiped out the company's net worth.
Why this matters
The company is effectively a shell with a market capitalization of only ₹3.00 crores. With no meaningful revenue and a qualified audit report, the business model faces an existential threat.
What we're watching
- Any evidence of license renewals or production restarts.
- Further auditor comments regarding the impairment of capital work.
- Management's ability to fund operations given the eroded equity.
The full read
MPS Pharmaa is a company in name only. For the fiscal year ending March 31, 2026, it reported a net loss of ₹1.02 crore on a negligible income of ₹3.56 lacs. The auditors have effectively lost faith in the balance sheet, issuing a qualified opinion on ₹53.80 lacs of unverified investments and ₹2.41 crore of stalled capital work-in-progress that may be worthless. With accumulated losses now at ₹19.04 crore, the equity base is almost entirely gone. Management claims they are working on license renewals and restarting production, but the auditors note that revenue has been absent for a long time. At a market capitalization of just ₹3.00 crore, the stock reflects the reality of a business that has stopped functioning. The numbers confirm a firm with extreme fundamental weakness and little to no path toward recovery.
Questions answered
- What is the current financial status of MPS Pharmaa?
- The company is in severe distress with accumulated losses of ₹19.04 crore, which has nearly eroded its entire net worth.
- Why did the auditors issue a qualified opinion?
- Auditors could not verify ₹53.80 lacs in investments and noted that ₹2.41 crore in capital work-in-progress requires technical evaluation for impairment.
- How much revenue did the company generate in FY26?
- Total income for the fiscal year was ₹3.56 lacs, a decline from the ₹4.77 lacs reported in the previous year.
- What is the scale of the company's market value?
- The company's market capitalization is approximately ₹3.00 crore, which is only slightly higher than its annual net loss.
Story so far
All notes on ADVIKLA →- 28 May 2026 · 2:08 PM IST MPS Pharmaa reports net loss of ₹1.02 cr as operations remain stalled
- today MPS Pharmaa equity nearly wiped out as core business remains stalled